Mechanism of action
Colchicine binds to the intracellular protein tubulin, preventing its polymerization into microtubules. Microtubules are essential components of the cytoskeleton and play critical roles in cell division, intracellular transport, and cell motility.
In the context of gout, urate crystals deposited in joints trigger an inflammatory response mediated by neutrophils. Colchicine disrupts neutrophil chemotaxis, adhesion, and phagocytosis by destabilizing microtubules. This prevents neutrophils from migrating to the site of crystal deposition and reduces the release of inflammatory mediators such as leukotriene B4 and pro-inflammatory cytokines.
Additionally, colchicine inhibits the NLRP3 inflammasome activation in macrophages, reducing IL-1β production—a key cytokine in gouty inflammation and familial Mediterranean fever. The drug also interferes with mitotic spindle formation, which accounts for its toxicity in rapidly dividing cells (gastrointestinal epithelium, bone marrow).
The anti-inflammatory effects are dose-dependent and occur at lower concentrations than those required for anti-mitotic effects, which contributes to its therapeutic utility in inflammatory conditions.
- Colchicine inhibits tubulin polymerization, preventing neutrophil migration and reducing NLRP3 inflammasome activation
- Most common adverse effect is dose-limiting diarrhea; narrow therapeutic index with risk of fatal overdose
- Contraindicated with strong CYP3A4/P-gp inhibitors (clarithromycin, cyclosporine) in renal/hepatic impairment due to toxicity risk
- First-line for familial Mediterranean fever; prevents AA amyloidosis with chronic use
- Myopathy and rhabdomyolysis risk increases when combined with statins, especially in CKD patients
- Low-dose regimen (1.2 mg then 0.6 mg 1 hour later) preferred for acute gout over historic high-dose protocols
- Used for gout prophylaxis during initiation of urate-lowering therapy (allopurinol/febuxostat) for 3-6 months
- Overdose presents in phases: GI symptoms, then multi-organ failure (bone marrow suppression, cardiovascular collapse); no specific antidote
Indications
Colchicine is FDA-approved for:
- Acute gout flares: First-line agent for treating acute gouty arthritis, particularly effective when initiated within 24-36 hours of symptom onset
- Gout prophylaxis: Prevents recurrent gout attacks during the initiation of urate-lowering therapy (allopurinol, febuxostat)
- Familial Mediterranean fever (FMF): Reduces frequency and severity of attacks and prevents amyloidosis in this autosomal recessive autoinflammatory disorder
Off-label uses
- Pericarditis: Reduces recurrence of acute and recurrent pericarditis, often used with NSAIDs or aspirin
- Behçet's disease: May reduce mucocutaneous manifestations
- Primary biliary cholangitis: Occasionally used, though ursodeoxycholic acid is preferred
- Scleroderma and other connective tissue diseases: Limited evidence for efficacy
Colchicine is not indicated for asymptomatic hyperuricemia. Dosing follows product labeling and should be adjusted for renal and hepatic impairment.
Pharmacokinetics
Absorption: Rapidly absorbed from the gastrointestinal tract with peak plasma concentrations reached in 0.5-2 hours. Bioavailability is approximately 45% due to first-pass metabolism and P-glycoprotein-mediated efflux in the intestine.
Distribution: Extensive tissue distribution with a large volume of distribution (5-8 L/kg). Colchicine concentrates in leukocytes, where it exerts its anti-inflammatory effects. Plasma protein binding is approximately 30-40%.
Metabolism: Primarily hepatic via CYP3A4, with demethylation to inactive metabolites. The parent drug and metabolites undergo enterohepatic recirculation, prolonging exposure.
Elimination: Excreted in bile (major route) and urine. The elimination half-life is approximately 27-31 hours in healthy individuals, allowing once or twice-daily dosing. Renal impairment significantly prolongs half-life and increases toxicity risk.
Important considerations: The drug is a substrate for both CYP3A4 and P-glycoprotein (P-gp). Co-administration with strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) or P-gp inhibitors (e.g., cyclosporine) dramatically increases colchicine levels and toxicity risk. Dose reduction or avoidance is necessary in patients with renal or hepatic impairment receiving these interacting drugs.
Adverse effects
Colchicine has a narrow therapeutic index, and adverse effects are common, especially with higher doses or in the setting of drug interactions.
Gastrointestinal (most common)
- Diarrhea (23-77% of patients): dose-limiting, often occurs before therapeutic effect
- Nausea and vomiting
- Abdominal pain and cramping
GI symptoms result from disruption of rapidly dividing intestinal epithelial cells and typically appear within 24 hours of initiation.
Hematologic
- Bone marrow suppression: leukopenia, thrombocytopenia, anemia (more common with chronic use or overdose)
- Aplastic anemia (rare)
Neuromuscular
- Myopathy and rhabdomyolysis: especially when combined with statins or in renal impairment; presents with proximal muscle weakness, elevated CK
- Peripheral neuropathy: axonal type, may be irreversible with chronic use
Hepatotoxicity
- Elevated liver enzymes, rare hepatic necrosis in overdose
Other
- Alopecia (with chronic use)
- Rash and hypersensitivity reactions (uncommon)
- Azoospermia (reversible, seen with prolonged therapy)
Overdose
Colchicine overdose is life-threatening and presents in three phases: (1) GI symptoms within 24 hours, (2) multi-organ failure (bone marrow suppression, cardiovascular collapse, renal failure) at 24-72 hours, and (3) recovery or death after one week. There is no specific antidote; treatment is supportive.
Contraindications and warnings
Absolute contraindications
- Concurrent use of P-glycoprotein or strong CYP3A4 inhibitors in patients with renal or hepatic impairment: risk of fatal toxicity
- Severe renal impairment (CrCl <30 mL/min) with hepatic impairment: dramatically increased drug accumulation
Warnings and precautions
Renal impairment: Dose reduction required; avoid in severe renal disease during gout prophylaxis. Hemodialysis does not remove colchicine effectively.
Hepatic impairment: Use with caution; dose adjustment necessary in moderate to severe disease.
Drug interactions: Life-threatening interactions with CYP3A4 inhibitors (macrolides, azole antifungals, protease inhibitors, grapefruit juice) and P-gp inhibitors (cyclosporine, ranolazine). Dose reduction or temporary discontinuation may be required.
Pregnancy: Category C (older classification). Limited human data; animal studies show teratogenicity at high doses. Use only if potential benefit justifies risk. FMF patients often continue therapy during pregnancy under specialist guidance to prevent disease flares.
Lactation: Excreted in breast milk; caution advised.
Elderly patients: Increased sensitivity due to reduced renal function; start with lower doses.
Neuromuscular toxicity: Monitor for myopathy, especially with statin co-administration. Discontinue if muscle pain, weakness, or elevated CK develops.
Blood dyscrasias: Monitor CBC periodically with long-term use.
Drug interactions
Colchicine is subject to clinically significant drug interactions due to its metabolism via CYP3A4 and transport by P-glycoprotein.
Strong CYP3A4 inhibitors (contraindicated or require dose reduction)
- Macrolide antibiotics: clarithromycin, erythromycin
- Azole antifungals: ketoconazole, itraconazole
- Protease inhibitors: ritonavir, atazanavir
- Grapefruit juice
These agents can increase colchicine levels 2-10 fold, leading to severe toxicity including fatal outcomes.
P-glycoprotein inhibitors
- Cyclosporine: profound increase in colchicine levels; combination often contraindicated
- Ranolazine, verapamil, diltiazem
Moderate CYP3A4 inhibitors
- Diltiazem, verapamil, fluconazole: dose reduction advised (typically 50% reduction)
Statins
- Increased risk of myopathy and rhabdomyolysis when combined with colchicine, particularly in patients with renal impairment. Monitor CK and symptoms closely.
Other interactions
- Fibrates (gemfibrozil, fenofibrate): additive myopathy risk
- Vitamin B12: chronic colchicine may impair B12 absorption; monitor levels in long-term users
CYP3A4 inducers
- Rifampin, phenytoin, carbamazepine: may reduce colchicine efficacy, though clinical significance is less well-established
Always review medication lists for potential interactions before prescribing colchicine, especially in patients with renal or hepatic impairment.
Clinical pearls
- Low-dose regimen for acute gout: Modern guidelines favor lower doses (1.2 mg initially, then 0.6 mg one hour later) rather than historic high-dose regimens, reducing GI toxicity without compromising efficacy.
- Timing matters: Colchicine is most effective for acute gout when started within 24-36 hours of flare onset. Delayed treatment reduces efficacy.
- Gout prophylaxis during ULT initiation: Start colchicine prophylaxis before initiating allopurinol or febuxostat and continue for 3-6 months to prevent mobilization flares as urate levels drop.
- FMF and amyloidosis prevention: Colchicine is the only proven therapy to prevent AA amyloidosis (renal complication) in FMF patients. Lifelong therapy is often required.
- Pericarditis: Increasingly used as adjunct to NSAIDs/aspirin for acute and recurrent pericarditis based on randomized trial evidence (COPE, ICAP, CORP trials). Reduces recurrence by approximately 50%.
- Diarrhea as a clinical endpoint: Some clinicians titrate colchicine to mild diarrhea as a surrogate for therapeutic dosing, though this is not evidence-based and increases toxicity risk.
- Fatal drug interactions: Always check for clarithromycin, azithromycin (less potent CYP3A4 inhibitor, safer alternative), and cyclosporine before prescribing. Numerous case reports of fatal colchicine toxicity exist.
- Renal dosing is critical: Many toxicities occur due to failure to adjust dose in CKD. In CrCl 30-60 mL/min, reduce gout prophylaxis dose; in CrCl <30 mL/min, avoid prophylactic use.
- Myopathy mimics gout: Colchicine-induced myopathy (especially with statins) can present with muscle pain misattributed to worsening gout. Check CK if weakness develops.
- Not first-line for all gout: NSAIDs and corticosteroids are reasonable alternatives for acute gout, especially when drug interactions or renal impairment complicates colchicine use.
Colchicine toxicity mnemonic – ABCD: Alopecia, Bone marrow suppression, Cramping/diarrhea (GI), Death (in overdose)
Practice questions
1. A 62-year-old man with a history of gout and chronic kidney disease (CrCl 40 mL/min) presents with an acute gout flare. He is started on colchicine. Three days later, he is admitted with severe diarrhea, vomiting, and pancytopenia. His medication list includes allopurinol, amlodipine, and clarithromycin (started 5 days ago for bronchitis). Which of the following best explains his presentation?
2. A 35-year-old woman with familial Mediterranean fever has been on colchicine 1.2 mg daily for 3 years. She now complains of progressive proximal muscle weakness and difficulty climbing stairs. Physical examination reveals 4/5 strength in hip flexors bilaterally. Laboratory studies show creatine kinase 2,400 U/L (normal <200). She also takes atorvastatin for hyperlipidemia. What is the most likely diagnosis?
3. A 55-year-old man with gout and atrial fibrillation on digoxin presents to the emergency department 5 days after starting clarithromycin for pneumonia. His primary care physician also started colchicine 0.6 mg twice daily for gout prophylaxis one week ago. He complains of severe diarrhea, muscle weakness, and confusion. Laboratory studies show WBC 2,100/μL, creatinine 2.8 mg/dL (baseline 1.1), and CK 8,500 U/L. Which drug interaction best explains his presentation?
Frequently asked questions
How does colchicine work for gout?
Colchicine binds to tubulin and prevents microtubule polymerization, which disrupts neutrophil migration to joints where urate crystals have deposited. By blocking neutrophil chemotaxis and reducing inflammasome activation, it decreases the inflammatory response responsible for gout flare symptoms. It also inhibits IL-1β release, a key mediator of gouty inflammation. Colchicine does not lower uric acid levels; it only treats inflammation.
What are the side effects of colchicine?
The most common side effect is gastrointestinal toxicity, particularly diarrhea, which affects up to 77% of patients and often limits dosing. Nausea, vomiting, and abdominal cramping are also frequent. Serious but less common effects include bone marrow suppression (leukopenia, thrombocytopenia), myopathy and rhabdomyolysis (especially with statins), peripheral neuropathy, and hepatotoxicity. Overdose can be fatal, causing multi-organ failure.
Can I take colchicine with antibiotics?
It depends on the antibiotic. Macrolides like clarithromycin and erythromycin are contraindicated with colchicine because they inhibit CYP3A4 and dramatically increase colchicine levels, risking fatal toxicity. Azithromycin is a weaker CYP3A4 inhibitor and is generally safer but still requires caution. Most other antibiotics (penicillins, cephalosporins, fluoroquinolones) do not significantly interact. Always inform your prescriber if you are taking colchicine before starting an antibiotic.
Is colchicine safe in kidney disease?
Colchicine requires dose reduction in chronic kidney disease because it is partly renally eliminated and toxicity risk increases significantly with impaired clearance. In moderate CKD (CrCl 30-60 mL/min), reduce the dose by 50%. In severe CKD (CrCl <30 mL/min), avoid chronic prophylactic use and use the lowest effective dose for acute gout with extreme caution. Combining colchicine with CYP3A4 or P-gp inhibitors in renal impairment is contraindicated due to risk of life-threatening toxicity.
Colchicine vs NSAIDs for gout — what is the difference?
Both are effective for acute gout flares. Colchicine works by inhibiting neutrophil migration via microtubule disruption, while NSAIDs (like indomethacin, naproxen) inhibit cyclooxygenase and reduce prostaglandin synthesis. Colchicine is preferred when NSAIDs are contraindicated (e.g., peptic ulcer disease, anticoagulation, severe renal impairment). NSAIDs tend to have fewer drug interactions but carry GI bleeding and cardiovascular risks. Colchicine has a narrower therapeutic window and requires careful attention to drug interactions and renal dosing.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: M04AC01
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.